IMVARIA Inc. announced that the company’s new platform Bronchosolve, an AI-powered diagnostic solution for assessment of suspicious pulmonary nodules, met the primary endpoints in the pivotal VIRTUAL-BRONCH Study, demonstrating significant improvement in the ability to diagnose lung cancer non-invasively.
Key results will be presented at a future scientific conference in 2026. The IMVARIA team conducted the pivotal VIRTUAL-BRONCH study of its new Bronchosolve solution to obtain data that underscores efficacy. This study focused on better non-invasive diagnosis of lung cancer in cases of suspicious pulmonary nodules, topline results showed increased correct cancer classification independently and in combination with expert radiologists and pulmonologists.
Bronchosolve is a completely automated, end-to-end platform with a streamlined workflow, eliminating the need for clinicians to do any manual data and imaging manipulation. This solution from IMVARIA is designed to advance a more accurate, non-invasive way to identify lung cancer through cutting-edge AI capabilities uniquely built by medical doctors.
IMVARIA’s pivotal VIRTUAL-BRONCH study analyzed cases from patients from multiple major cancer centers and health systems in the U.S. The objective was to assess Bronchosolve’s ability to diagnose lung cancer non-invasively through an efficient workflow, in both screening and non-screening cases with suspicious pulmonary nodules. The primary endpoints were met.
For more information about IMVARIA, click here.
Read the full announcement on Businesswire
